On Monday, Cybin released the financial results for its first quarter, ending June 30, 2023. As of June 30, 2023, the company had $9.4 million (Canadian...
Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 The post Cybin...
Cybin reports first quarter financial results and business highlights, including updates on key trials. The post Cybin Reports Q1 Financial Results and...
-Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
Toronto-based Cybin Inc. (NYSE: CYBN) (NEO: CYBN) increased its losses for its first fiscal quarter of 2023 to C$14.5 million, up from C$13.1 million a...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed The post News...
Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
On Monday, publicly-traded psychedelic company Cybin announced an overnight public offering, and its stock paid the price. This came as no surprise to...
Psychedelic medicine is making enormous strides. But many barriers still exist that hinder individuals from accessing psychedelic therapy. The post Barriers...